Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) SEC filings page on Stock Titan brings together the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents provide structured insight into KalVista’s financial condition, governance, capital structure and key events related to its development and commercialization of EKTERLY (sebetralstat), an oral plasma kallikrein inhibitor for hereditary angioedema (HAE).
Investors can review Form 8‑K current reports in which KalVista announces material events, such as FDA approval of EKTERLY, preliminary and quarterly financial results, appointments of new executives and directors, and the issuance of 3.250% Convertible Senior Notes due 2031. These filings describe terms of financing arrangements, board and committee changes, executive employment agreements and stock‑based inducement awards.
Proxy materials such as the DEF 14A definitive proxy statement detail corporate governance matters, including annual meeting agendas, director elections, advisory votes on executive compensation and auditor ratification. They also outline board structure, committee responsibilities and stockholder voting procedures. Periodic reports referenced in the proxy statement, such as the company’s Annual Report on Form 10‑K, provide audited financial statements and broader business discussion.
Through Stock Titan, users can access these filings as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections, including descriptions of convertible note covenants, events of default, change‑in‑control provisions and compensation arrangements. The filings page is also a key source for tracking any future Forms 3, 4 and 5 that would report insider transactions in KalVista common stock, as well as 10‑Q and 10‑K reports that update on revenue from EKTERLY, research and development spending and liquidity.
By reviewing KalVista’s SEC filings with the help of AI explanations, investors can better understand how the company finances its operations, governs its business and discloses risks and opportunities associated with its rare‑disease portfolio.
Palleiko Benjamin L reported multiple insider transaction types in a Form 4 filing for KALV. The filing lists transactions totaling 17,594 shares at a weighted average price of $15.70 per share. Following the reported transactions, holdings were 428,286 shares.
KalVista Pharmaceuticals, Inc. reported that its Chief Operations Officer, Arif Bilal, received a grant of 49,000 restricted stock units (RSUs) on January 16, 2026. Each RSU represents a contingent right to receive 1 share of KalVista common stock upon settlement for no cash consideration.
The RSUs vest in equal installments over four years. Specifically, 1/16 of the total RSUs will vest on each quarterly anniversary of the vesting commencement date, starting May 22, 2026, as long as Bilal’s service with the company does not terminate. Following this grant, he beneficially owns 49,000 RSUs directly.
KalVista Pharmaceuticals reported that its Chief Commercial Officer, Nicole Sweeny, received an equity award in the form of restricted stock units. On January 16, 2026, she was granted 100,000 restricted stock units (RSUs), each representing the right to receive one share of KalVista common stock for no cash payment upon settlement. The RSUs are scheduled to vest in equal installments, with 1/16 of the total amount vesting on each quarterly anniversary of the vesting commencement date, beginning on May 22, 2026, as long as her service with the company continues. Following this grant, she holds 100,000 derivative securities directly in the form of RSUs.
KalVista Pharmaceuticals reported an equity award for its Chief Financial Officer, Brian Piekos. On January 16, 2026, he received 100,000 restricted stock units (RSUs), each representing the right to receive one share of KalVista common stock for no cash consideration upon settlement.
The RSUs are scheduled to vest in equal installments, with 1/16 of the total vesting on each quarterly anniversary of the vesting commencement date starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities in the form of RSUs, held directly.
KalVista Pharmaceuticals’ chief medical officer receives new equity award. Paul K. Audhya, the company’s Chief Medical Officer, reported a grant of 100,000 restricted stock units on January 16, 2026. Each RSU represents the right to receive 1 share of KalVista common stock upon settlement for no cash payment. The RSUs will vest over four years, with 1/16 of the total units vesting on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities directly.
KalVista Pharmaceuticals, Inc. reported that its Chief Executive Officer and director, Benjamin L. Palleiko, received a grant of 325,000 restricted stock units (RSUs) on January 16, 2026. Each RSU represents a contingent right to receive one share of KalVista common stock for no cash consideration when the units settle.
According to the vesting terms, 1/16 of the RSUs will vest on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company does not terminate. Following this award, Palleiko directly holds 325,000 derivative securities in the form of RSUs.
KalVista Pharmaceuticals, Inc. received an updated ownership disclosure from Point72-related entities and Steven A. Cohen, who report beneficial ownership of 2,781,902 shares of common stock, representing 5.5% of the company. The shares are held by Point72 Associates, LLC, with investment and voting power managed by Point72 Asset Management, L.P., whose general partner is Point72 Capital Advisors, Inc., all controlled by Mr. Cohen.
This filing is Amendment No. 1 to a prior Schedule 13G and is made to correct the beneficial ownership previously disclosed. The reporting persons state that the securities are not held for the purpose of changing or influencing control of KalVista Pharmaceuticals.
KalVista Pharmaceuticals, Inc. disclosed that investment entities associated with Point72 Asset Management, L.P., including Point72 Capital Advisors, Inc. and Steven A. Cohen, beneficially own 2,523,493 shares of its common stock. This position represents 4.9% of the outstanding common stock as of the close of business on January 9, 2026. The shares are held by an investment fund managed by Point72 Asset Management, which has shared voting and dispositive power over the position.
The reporting persons state that the securities were not acquired for the purpose of changing or influencing control of KalVista and are reported on a passive Schedule 13G basis. Each of Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen disclaims being the beneficial owner of the shares for certain legal purposes, even though they may be deemed to share investment and voting power under the securities laws.
KalVista Pharmaceuticals reported preliminary global net revenue of approximately $35 million for the quarter and $49 million for the eight‑month transition period ended December 31, 2025. These figures are early estimates and rely on the company’s financial closing procedures and the completion of an audit of its financial statements for that transition period. The company emphasized that the final audited results could differ materially from these preliminary numbers. KalVista also released a press release and an updated corporate presentation, which are attached as exhibits to this report.
KalVista Pharmaceuticals (KALV)87,390 shares of common stock at an exercise price of $0.0043 per share, coded as transaction type "M" (option exercise). After this transaction, the officer directly beneficially owned 220,964 shares of KalVista common stock. The related employee stock option, which was 100% vested, was fully exercised and no derivative securities remained beneficially owned.